Here are nine observations:
1. In 2017, the market is valued at $2 billion.
2. The market is expected to grow at a compound annual growth rate of 6.4 percent through 2027.
3. Rechargeable SCS are anticipated to continue dominating the market, with sales reaching $2.53 billion by 2027.
4. Non-rechargeable SCS will likely grow at a 4.6 percent CAGR.
5. The SCS application for failed back surgery syndrome will remain dominant throughout the forecast period. Sales will likely exceed $1 billion in 2017.
6. The complex regional pain syndrome comes in second for SCS application, with sales expected to grow at a 5.8 percent CAGR through 2027.
7. North America will lead the global market, with sales hitting $3 billion by 2027.
8. Western Europe comes in second, growing at a 6.1 percent CAGR through 2027. Eastern Europe and Japan will both grow at a 6 percent CAGR through 2027.
9. Boston Scientific, Medtronic, St Jude Medical, Nevro, Nuvectra, Stimwave and Saluda Medical lead the market.
More articles on devices:
Wright Medical enrolls 1st patient in U.S. Infinity Total Ankle System study: 5 points
InVivo cuts 39% of workforce, reports $9.4M net loss in Q3: 5 things to know
Global spine implants market to increase at 5.29% CAGR through 2020: 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
